Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations

Taverna, C; Bargetzi, M; Betticher, D; Gmür, J; Gregor, M; Heim, D; Hess, U; Ketterer, N; Lerch, E; Matthes, T; Mey, U; Pabst, T; Renner, C (2010). Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations. Swiss medical weekly, 140, w13054. Muttenz: EMH Schweizerischer Ärzteverlag 10.4414/smw.2010.13054

Full text not available from this repository. (Request a copy)

The treatment of multiple myeloma has undergone significant changes in the recent past. The arrival of novel agents, especially thalidomide, bortezomib and lenalidomide, has expanded treatment options and patient outcomes are improving significantly. This article summarises the discussions of an expert meeting which was held to debate current treatment practices for multiple myeloma in Switzerland concerning the role of the novel agents and to provide recommendations for their use in different treatment stages based on currently available clinical data. Novel agent combinations for the treatment of newly diagnosed, as well as relapsed multiple myeloma are examined. In addition, the role of novel agents in patients with cytogenetic abnormalities and renal impairment, as well as the management of the most frequent side effects of the novel agents are discussed. The aim of this article is to assist in treatment decisions in daily clinical practice to achieve the best possible outcome for patients with multiple myeloma.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Pabst, Thomas Niklaus

ISSN:

1424-7860

Publisher:

EMH Schweizerischer Ärzteverlag

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:09

Last Modified:

02 Mar 2023 23:20

Publisher DOI:

10.4414/smw.2010.13054

PubMed ID:

20458652

Web of Science ID:

000282844500002

URI:

https://boris.unibe.ch/id/eprint/1087 (FactScience: 201834)

Actions (login required)

Edit item Edit item
Provide Feedback